TABLE 5.

Studies investigating the effects of blocking eCB actions at CB1R or enhancing eCB levels on sexual behavior expression of sexually active male rats.

Drug	Mechanism of action	Dose and administration route (latency)	Effects on MSB	References
AM251	CB1R antagonist	1, 2 and 5 mg/kg, i.p. (−90 min)	5 mg/kg: ↓ #I; ↓ EL	Gorzalka et al., 2008
AM251	CB1R antagonist	0.1, 0.3, 1.0, and 3.0 mg/kg, i.p.	1 and 3 mg/kg: ↓#M, ↓EL, ↑#E/1h 3 mg/kg: ↓IL	Canseco-Alba and Rodríguez-Manzo, 2014
AM404	Inhibitor of AEA reuptake and FAAH inhibitor	1, 2 and 5 mg/kg, i.p. (−90 min)	5 mg/kg: ↑ IL	Gorzalka et al., 2008
URB597	FAAH inhibitor	0.1, 0.3 and 0.5 mg/kg, i.p.	No effect	Gorzalka et al., 2008
SR 141716A (Rimonabant)	CB1R antagonist	0.5, 1 and 2 μg/rat intra-PVN	Induced spontaneous penile erection	Melis et al., 2004

eCB, endocannabinoid; CB1R, cannabinoid receptor 1; FAAH, fatty acid amide hydrolase; AEA, anandamide; i.p., intraperitoneal; intra-PVN, infused into the hypothalamic paraventricular nucleus. Sexual parameters: ML, mount latency; IL, intromission latency; EL, ejaculation latency; #M, number of mounts; #I, number of intromissions, #E, number of ejaculations.